

## HTL launches new CSR strategy

*HTL's new corporate social responsibility strategy will focus on accelerating the company's commitment to its environment, local ecosystem and employees.*

*HTL's engagements have been awarded an Ecovadis gold medal in 2023 and are certified by ISO 14001:2015.*

**Javené, October 9, 2023** – HTL, pioneer and world leader in the development and production of innovative pharmaceutical-grade biopolymers, announces its new corporate social responsibility (CSR) strategy. It aims to accelerate the company's commitment to its entire ecosystem and transform its activity into a positive and sustainable force. The strategy includes 19 commitments, divided into three priority areas: responsibility to preserve the environment, exemplarity with employees, and citizenship with civil society.

*"The foundations and approach of our new corporate social responsibility strategy will guide all our commercial, industrial and internal activities in the future. We are very proud that our existing commitments that have been adopted, have been recognized by international organizations such as Ecovadis,"* **François Fournier, Chief Executive Officer of HTL Biotechnology.**

Within a regulated pharmaceutical industry, HTL has set itself ambitious targets for reducing its environmental footprint to combat climate change and to preserve resources. Between 2022 and 2023, HTL aims to reduce its consumption of water per kilo of hyaluronic acid produced by 10%, and use of fossil fuels by 15%. It also aims to continue to control aqueous and atmospheric discharges and prevent the risks of air, water and soil pollution. To achieve these objectives, HTL is constantly looking for new solutions, including the optimization of cleaning processes, the reduction detergents use, and the installation of 600m<sup>2</sup> of solar panels on its production plant.

*"The respect for the environment and the preservation of resources, particularly water, have been central considerations that HTL have had in place for several years in order to reduce the impact of our industrial activities. We will continue to ensure this as a priority as we develop our production capacities using new processes and technologies, while developing innovative projects, some of which are unique in the pharmaceutical sector.,"* **says Christophe Coyard, HTL's Chief Industrial Performance Officer, in charge of CSR at HTL.**

All these commitments, as well as the projects already implemented over the past few years, have been recognized by international institutions and organizations. In 2023, HTL was awarded a gold medal by Ecovadis, a sustainability and corporate social responsibility rating organization, and was certified by the ISO 14001:2015 environmental management system standard. In addition to these commitments, in 2022 HTL joined the United Nations Global Compact, the largest international initiative for sustainable development and corporate social responsibility.

###

### **About HTL**

HTL is a pioneering biotech in the bioproduction of hyaluronic acid and a fast-growing industrial player. In 30 years, HTL has become the world leader in the development and responsible production of customized, innovative pharmaceutical-grade biopolymers, working with leading companies in the pharmaceutical and medical device

sectors to transform the lives of millions of patients worldwide. HTL's production and R&D activities are based in its historic plant in Brittany (France), while having opened a production unit in the USA, an office in China and a subsidiary in Singapore. Find out more about HTL: <https://htlbiotech.com/>

**Press contacts**

**Nathalie Chevallon – HTL**

[ncevallon@htlbiotech.com](mailto:ncevallon@htlbiotech.com) / +33 7 61 45 26 85

**Alexandra Guerreiro – APCO Worldwide**

[aguerreiro@apcoworldwide.com](mailto:aguerreiro@apcoworldwide.com) / +33 6 13 34 61 53